Page last updated: 2024-08-25

zoledronic acid and Bone Loss, Osteoclastic

zoledronic acid has been researched along with Bone Loss, Osteoclastic in 259 studies

Research

Studies (259)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (3.47)18.2507
2000's120 (46.33)29.6817
2010's107 (41.31)24.3611
2020's23 (8.88)2.80

Authors

AuthorsStudies
Martin, MB; Oldfield, E; Szabo, CM1
Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L1
Kotsikorou, E; Oldfield, E1
Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y1
Blangy, A; Cherfils, J; Ferrandez, Y; Gilardone, M; Morel, A; Morko, J; Mounier, L; Roche, D; Vääräniemi, J1
Cheng, YT; Huang, XL; Li, JP; Liao, J; Liu, C; Shi, XM; Zhou, Q1
Azetsu, Y; Chatani, M; Ikeda, M; Karakawa, A; Sakai, N; Suzuki, N; Takami, M; Takizawa, H1
Arana-Chavez, VE; Bradaschia-Correa, V; de Faria, LP; Rezende-Teixeira, P; Ribeiro-Santos, GC1
Ding, D; Feng, G; Jin, Q; Ma, L; Pei, X; Wang, L; Yan, J; Yang, Y; Zhou, Y1
Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M1
Horne, AM; Jabr, A; Liu, M; Mellar, A; Reid, IR; Wen, J1
Teles, AR; Zafeiris, CP; Zafeiris, ΕP; Zogakis, PN1
Harsløf, T; Jørgensen, NR; Langdahl, B; Sølling, AS1
Cai, X; Chai, Z; Chen, J; Dou, R; Du, C; Hu, Y; Jia, F; Liu, X; Liu, Y; Ruan, L; Zhang, J; Zhang, X1
Chen, B; Chen, F; Chen, J; Chen, X; Feng, Z; Huang, B; Kong, X; Li, J; Song, H; Tao, S; Wei, X; Yao, Q; You, T; Yu, H; Zhang, X; Zhao, F; Zheng, L; Zheng, Z1
Arnett, TR; Davies, BK; Hibbert, AP; Holdsworth, G; Orriss, IR; Roberts, HC; Roberts, SJ; Tickner, JC1
Chen, HL; Hu, JP; Lan, L; Li, JF; Li, Q1
Anastasilakis, AD; Appelman-Dijkstra, NM; Makras, P; Papapoulos, SE; Polyzos, SA1
Kushima, C; Nakazato, M; Uchida, T; Yamaguchi, H; Yonekawa, T1
Kumar, A; Qayoom, I; Teotia, AK1
Ando, Y; Arai, E; Hase, T; Ikuta, K; Ishiguro, N; Kikumori, T; Maeda, O; Mitsuma, A; Nishida, Y; Shimokata, T; Sugishita, M; Urakawa, H1
Hu, JB; Lu, CB; Sang, HX; Wang, FQ; Yang, XJ; Yang, Z; Zhang, Y; Zou, JW1
Bianchi, G; Camellino, D; Girasole, G; Giusti, A; Iervasi, E; Papapoulos, SE; Saverino, D1
Dong, W; Gu, Y; Jia, S; Liang, Y; Lin, Y; Qi, M; Zuo, G1
Oryan, A; Sahvieh, S1
Kasai, H; Mori, Y; Ose, A; Shiraki, M; Tanigawara, Y1
da Silva Martins, C; Dantas, HV; de Carvalho Leitão, RF; de Castro Brito, GA; de Sousa Ferreira, VC; de Sousa, FB; de Sousa, FRN; Girão-Carmona, VCC; Goes, P1
Cheng, YT; Hong, W; Huo, H; Liao, DJ; Liao, J; Ma, H; Tang, ZL; Zellmer, L; Zhou, Q1
Liel, Y; Plakht, Y; Tailakh, MA1
Allen, MR; Alvarez, MB; Bidwell, JP; Burr, DB; Childress, P; Condon, KW; Davis, H; He, Y; Hernandez-Buquer, S; Plotkin, LI; Robling, AG; Shao, Y; Stayrook, KR; Warden, SJ; Wek, RC; Yang, FC1
Antoniali, C; de Campos, N; Ervolino, E; Fucini, SE; Furlaneto, FAC; Messora, MR; Nagata, MJH; Pola, NM; Santinoni, CS1
Lüftner, D; Niepel, D; Steger, GG1
Dai, K; Hao, Y; Li, G; Pei, J; Wang, L; Yuan, G; Zhang, L1
Baas, J; Jakobsen, T; Kold, S; Rahbek, O; Shiguetomi-Medina, J; Soballe, K1
Dezawa, A; Kamijo, R; Karakawa, A; Miyamoto, A; Nakamura, S; Shibuya, I; Takami, M1
Ge, XY; Hao, KY; Jiang, X; Lin, Y; Ma, T; Zhang, BR; Zhang, Y1
Aguirre, JI; Bhattacharyya, N; Castillo, EJ; Jiron, JM; Kimmel, DB; Mendieta Calle, JL; Messer, JG; Van Poznak, C1
Ishiguro, M; Kasai, H; Mori, Y; Ose, A; Serada, M; Shiraki, M; Tanigawara, Y1
Jia, N; Jin, X; Li, P; Shen, Y; Xu, D; Yang, H1
Cheung, LC; Chua, GA; Foley, B; Ford, J; He, B; Howlett, M; Hughes, AM; Kees, UR; Kotecha, RS; Mullighan, CG; Oommen, J; Singh, S; Skut, P; Tickner, J; Wells, JE1
Hadji, P; Hars, O; Kann, PH; Kyvernitakis, I; Thomasius, F1
Charlesworth, G; Daroszewska, A; Prior, A; Ralston, SH; Rose, K; Rose, L; Sarsam, N; van 't Hof, RJ1
Akpinar, F; Aktas, I; Bilgic, B; Bostan, AB; Illeez, OG; Ozkan, FU; Ozkan, K1
Dong, W; Feng, X; Liu, H; Qi, M; Wang, Y1
Gui, K; Ji, W; Jiang, Z; Liang, G; Ma, J; Xiong, M; Yu, W; Yuan, F; Zeng, X; Zhang, C; Zhang, F; Zhao, M1
Alvarenga, JC; Araújo, MJCLN; Custódio, MR; David-Neto, E; Dos Reis, LM; Elias, RM; Graciolli, FG; Jorgetti, V; Marques, IDB; Moysés, RMA; Pereira, RMR1
Geng, D; Guo, X; Liu, Y; Xu, Y; Yang, H; Zhou, W1
Body, JJ; Costa, L; Gonzalez-Suarez, E; Niepel, D; Terpos, E; von Moos, R1
Ebbinghaus, M; Eitner, A; Hess, A; Hilger, I; Kamradt, T; Müller, S; Schaible, HG; Segond von Banchet, G; Wank, I1
Bonnet, N; Ferrari, S; Lesclous, P; Saffar, JL1
Basile, G; Brancatelli, S; Catalano, A; Cucinotta, D; Lasco, A; Morabito, N1
Carlton, MM; Dirksen, WP; Hildreth, BE; Lanigan, LG; London, CA; Martin, CK; Pillai, SP; Rosol, TJ; Simmons, JK; Toribio, RE; Werbeck, JL1
Bolland, M; Gamble, G; Grey, A; Horne, A; Mihov, B; Reid, IR; Wong, S1
Damron, TA; Keenawinna, L; Mann, KA; Oest, ME; Spadaro, J1
Bredeson, CN; Burns, LJ; DeFor, TE; Hari, P; Vesole, DH1
Anghel, R; Bachmann, A; Bekşac, M; Brodowicz, T; Finek, J; Komadina, R; Krzemieniecki, K; Lang, I; Marencak, J; Pecherstorfer, M; Rordorf, T; von Moos, R; Vrbanec, D; Zielinski, C1
Bakhous, A; Waheed, S; Zhu, H1
Abe, M; Kawazoe, K; Kujime, T; Minakuchi, K; Okada, N; Shinohara, Y; Teraoka, K1
Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN1
Baas, J; Barckman, J; Bechtold, JE; Søballe, K; Sørensen, M1
Endo, Y; Kiyama, T; Kuroishi, T; Oizumi, T; Okada, S; Sasaki, K; Sato, E; Sugawara, S; Takahashi, T; Tanaka, Y1
Debiais, F1
Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H1
Barba-Recreo, P; Burgueño, M; Del Castillo Pardo de Vera, JL; García-Arranz, M; Yébenes, L1
Crockett, JC; Das, S; Edwards, PA; Rogers, MJ1
Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED1
Aati, O; Chhana, A; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; House, ME; McQueen, FM; Reid, IR; Roger, M1
Ando, T; Cates, JM; Cole, HA; Haro, H; Ohba, T; Schoenecker, JG; Schwartz, HS; Slosky, DA1
Irwig, MS1
Alves, A; Arnoldi, J; Procter, P1
Guo, X; Lu, X; Ni, B; Shi, J; Xie, N; Zeng, Y; Zhu, M; Zhu, Y1
Bobyn, J; Kathy, M; Little, DG; Rasch, A; Schindeler, A1
Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K1
Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ1
Ding, S; Li, J; Li, P; Li, R; Qi, M; Xu, C1
Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Meek, J; Ottewell, PD; Wang, N1
Aghaloo, TL; Bezouglaia, O; Cheong, S; Cirelli, JA; de Molon, RS; Dry, SM; Pirih, F; Tetradis, S1
Buckwalter, JA; Fredericks, DC; Malandra, AE; Morcuende, J; Odgren, PR; Otero, JE; Stevens, JW1
Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK1
Kang, MK; Kim, RH; Kim, T; Lee, C; Liu, H; Park, NH; Park, S; Shi, S; Shin, KH; Williams, DW; Wu, H; Yagita, H; Yang, P1
Gao, AC; Ghosh, PM1
Kettenberger, U; Pioletti, DP; Procter, P; Ston, J; Thein, E1
Dong, W; Li, P; Lin, J; Qi, M; Sun, H; Zhang, P1
Askmyr, M; Baker, EK; Ebeling, PR; Harrison, SJ; Jovic, T; Neeson, P; Purton, LE; Quach, JM; Ritchie, D; Walsh, NC1
Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G1
Hashimoto, A; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Ono, K; Sato, T; Takada, K; Takimoto, R; Tatekoshi, A1
Chunfeng, X; Hong, S; Jueshan, L; Mengchun, Q; Wei, D; Xiaojie, F1
Aghaloo, TL; Bezouglaia, O; Boyce, RW; de Molon, RS; Dry, SM; Dwyer, D; Kostenuik, P; Pirih, FQ; Shimamoto, H; Tetradis, S1
Gomes Filho, JE; Kobayashi, J; Kobayashi, M; Matsuda, S; Ohba, S; Sano, K; Wayama, MT; Yoshida, H; Yoshimura, H1
Jiao, K; Kumar, S; Li, JY; Messer, R; Niu, LN; Pashley, DH; Pei, DD; Pramanik, C; Tay, FR; Yuan, H1
Brüel, A; Henriksen, K; Thomsen, JS; Vegger, JB; Wendelboe, MH1
Jiang, Y; Li, M; Liu, Y; Lv, F; Ma, DD; Song, LJ; Wang, JW; Wang, JY; Wang, O; Xia, WB; Xing, XP; Xu, XJ1
Nakamura, T; Shiraki, M; Suzuki, H; Tanaka, S; Ueda, S1
Cheng, N; Ha, S; Hong, C; Kim, R; Kwon, T; Lee, D; Lim, R; Olson, J; Park, J; Tetradis, S; Ting, K; Zhang, X1
Boyce, BF; Li, J; Li, X; Pei, L; Sun, W; Wang, M; Wang, Z; Xing, L; Zhang, H1
Alon, US; Freundlich, M1
Fukawa, T; Kamiya, S; Wada, S1
Body, JJ3
Greiner, S; Kadow-Romacker, A; Schmidmaier, G; Wildemann, B1
Buijs, JT; Löwik, CW; Papapoulos, SE; Que, I; van der Pluijm, G1
Cunnane, G; Delaney, H; Doran, MF; Sheane, BJ1
Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT1
Cho, SK; Lee, FY; Seo, SW; Storer, SK1
Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C1
Amir, E; Clemons, MJ; Dranitsaris, G; Simmons, CE; Trinkaus, M1
Coleman, RE; Winter, MC1
Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V1
Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M1
Bubbear, JS; Ferguson-Pell, M; Gall, A; Keen, RW; Middleton, FR; Swaminathan, R1
Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G1
Bolland, M; Gamble, G; Grey, A; Horne, A; Reid, IR; Wattie, D1
Abildgaard, N; Delaisse, JM; Lund, T; Plesner, T1
Athanasou, N; Balke, M; Campanacci, L; Gebert, C; Gibbons, M; Hogendoorn, P; Kroep, J; Picci, P; Taylor, R; Wass, J1
Aapro, M; Coleman, R; Gnant, M; Hadji, P; Lipton, A1
Pozzi, S; Raje, N1
Lanigan, LG; Martin, CK; Rosol, TJ; Thudi, NK; Toribio, RE; Werbeck, JL; Wolfe, TD1
Black, DM; Bucci-Rechtweg, C; Grbic, JT; Lyles, KW; McClung, M; Orwoll, E; Reid, DM; Su, G1
Keech, F; May, RJ; McLernon, DJ; Reid, DM; Rogers, MJ; Simpson, WG; Thompson, K; Vinod, K1
Brennan, O; Kennedy, OD; Lee, TC; McNamara, LM; O'Brien, FJ; Rackard, SM1
Berd, Y; He, W; Jensen, AB; Lombardi, A; Mehta, A; Ramirez, G; Song, Y; Wang, H; Wynne, C1
Hadji, P2
Ikebe, T; Kajiya, H; Kimachi, K; Nakayama, S; Okabe, K1
Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R1
Chen, LK; Hou, X; Huang, Y; Li, S; Liao, H; Liu, JL; Xu, F; Xue, C; Zhang, L; Zhao, HY; Zhao, YY1
Green, JR; Guenther, A1
Chen, Y; Liang, X; Liu, D; Meng, YH; Peng, Y; Wang, H1
Koul, HK; Koul, S; Meacham, RB1
Ashton, JM; Becker, MW; Calvi, LM; Frisch, BJ; Jordan, CT; Xing, L1
Athanasou, NA; Cheng, X; Estrada, FM; Gordon, S; Hemingway, F; Knowles, HJ1
Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K1
Amodeo, V; Bazan, V; Caruso, S; Corsini, LR; Di Gaudio, F; Fanale, D; Insalaco, L; Margarese, N; Russo, A; Santini, D; Terrasi, M1
Bauer, DC; Schousboe, JT1
Hsu, LH; Lin, FH; Lu, DH; Wang, CC; Wu, CC; Yang, KC1
Draenert, GF; Huetzen, DO; Kämmerer, PW; Nacu, V; Palarie, V; Wagner, W1
De Stefano, V; Logroscino, CA; Proietti, L; Scaramuzzo, L; Tamburrelli, FC1
Bolland, MJ; Gamble, G; Grey, A; Horne, A; House, M; Reid, IR; Wattie, D1
Brown, R; Cohen, A; Mancini, D; McMahon, DJ; Pandit, K; Restaino, S; Shane, E; Staron, RB; Stein, EM; Verna, EC; Young, P; Zhang, C1
Cornish, J; Dalbeth, N; Horne, A; House, ME; Pool, B; Reid, IR; Stewart, A1
Scott, DF; Smith, RR; Woltz, JN1
Chang, SX; Fan, JZ; He, YM; Li, GW; Tian, YN; Xu, Z1
Belfrage, O; Isaksson, H; Tägil, M1
Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M1
Cataldo, VD; Dong, W; Fanale, MA; Fayad, LE; Fowler, N; Hagemeister, FB; Jimenez, C; Kwak, LW; McLaughlin, P; Murphy, WA; Neelapu, S; Pro, B; Romaguera, J; Samaniego, F; Sanjorjo, P; Shah, J; Thompson, MA; Toth, B; Westin, JR1
Hortobagyi, GN1
Hussar, DA1
Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ1
Major, P1
Berenson, JR3
Goa, KL; Wellington, K1
Harland, SJ; Oosterlinck, W; Rosen, L1
Evans, GP; Glatt, M; Green, JR; Hornby, SB; Hornby, SL; Pataki, A1
Green, JR2
Saad, F3
Rosen, LS1
Chung, G; Keen, RW1
Denoyelle, C; Hong, L; Soria, C; Soria, J; Vannier, JP1
Chole, RA; Ebmeyer, J; Faddis, BT; Hildmann, H; Jung, JY; Sudhoff, H1
Pitts, WR1
Avvisati, G; Battistoni, F; Borzomati, D; Coppola, R; Dicuonzo, G; Gavasci, M; Rocci, L; Santini, D; Tonini, G; Vincenzi, B1
Coleman, R; Croucher, P; Jagdev, S1
Fraser, WD; Mishra, V; Peter, R1
Evans, GP; Glatt, M; Green, JR; Hornby, SB; Pataki, A1
Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM1
Bartsch, R; Hussian, D; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC1
Figgitt, DP; Perry, CM1
Goldring, SR; Gravallese, EM1
Bergmeister, H; Gasser, J; Görtz, B; Hayer, S; Herrak, P; Kollias, G; Redlich, K; Reiter, E; Schett, G; Smolen, JS1
Gillespie, MT; Glatt, M; Green, JR; Martin, TJ; Romas, E; Schlict, S; Sims, NA1
Bukowski, RM; Colombo-Berra, A; Lipton, A; Rosen, L; Urbanowitz, G; Zheng, M1
Parker, CC1
Ambler, G; Cowell, CT; Högler, W; Little, D; McQuade, M; Yap, F1
Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH1
Alonso, B; Bouler, JM; Bujoli, B; Daculsi, G; Faucheux, C; Gauthier, O; Grimandi, G; Guicheux, JJ; Janvier, P; Josse, S; Laïb, S; Massiot, D; Pilet, P; Soueidan, A1
Harvey, HA1
Brahmbhatt, V; Patel, K; Ramu, V1
Gralow, J1
Cortizo, AM; McCarthy, AD; Vaisman, DN1
Lipton, A2
Schwartz, JE1
Brown, JE; Coleman, RE; Cook, R; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Seaman, J; Smith, M; Zheng, M1
Bereiter, H; Heckelei, A; Henschke, F; Hilken, G; Löer, F; Saxler, G; Sprecher, C; von Knoch, F; von Knoch, M; Wedemeyer, C1
Little, DG; McDonald, M; McEvoy, T; Peat, R; Sharpe, IT; Williams, P1
Alimonti, A; Bordignon, V; Carlini, P; Cognetti, F; Cordiali Fei, P; D'Agosto, G; Di Cocco, B; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Papaldo, P; Salesi, N; Trento, E1
Deftos, LJ1
Briody, JN; Eisman, JA; Gardiner, EM; Little, DG; McEvoy, A; Smith, EJ; Smith, NC1
Lipton, A; Saad, F2
Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B1
Rizzoli, R; Uebelhart, B1
Barkley, CS; Bilhartz, DL; Given, RW; Julian, SR; Karlin, GS; Lacerna, LV; McWhorter, LT; Metzger, C; Polascik, TJ; Vestal, JC1
Arcara, C; Badalamenti, G; Casuccio, A; Cicero, G; Di Fede, G; Fulfaro, F; Gebbia, N; Intrivici, C; Leto, G; Rini, GB; Russo, A; Valerio, MR; Vitale, A1
Suzuki, M; Tomoo, T1
Hosking, D1
Cornford, P; Manikandan, R; Mistry, R; Philip, J1
Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E1
Aspenberg, P; Astrand, J; Tägil, M1
Kaise, H; Kohno, N1
Angeletti, S; Brown, JE; Budillon, A; Caraglia, M; Coleman, RE; Dicuonzo, G; Hannon, RA; Holen, I; La Cesa, A; Santini, D; Tonini, G; Vincenzi, B1
Anjrini, AA; Badran, Z; Bouler, JM; Daculsi, G; Faucheux, C; Grimandi, G; Guicheux, J; Pilet, P; Soueidan, A1
Brufsky, A1
Aspenberg, P; Astrand, J; Harding, AK; Tägil, M1
D'Souza, AB; Ebeling, PR; Grigg, AP; Szer, J1
Barrick, M1
Anagnostopoulos, A; Kiamouris, C; Konstantopoulos, K; Spyropoulou, E; Stoupa, E; Terpos, E; Voskaridou, E1
Greiner, S; Kadow-Romacker, A; Lübberstedt, M; Schmidmaier, G; Wildemann, B1
Carlsten, H; Ohlsson, C; Tarkowski, A; Verdrengh, M1
Bandeira, F; Colares, V; Griz, L1
Sakurai, T1
Iguchi, H1
Beamer, E; Kriegman, A; Lindsay, R; Saag, K; Zhou, W1
Loveridge, N; Poole, KE; Reeve, J; Rose, CM; Warburton, EA1
Ballard, P; Beck, T; BrintzenhofeSzoc, K; Caminis, J; Dapthary, M; Shapiro, J; Smith, B1
Gondo, T; Hashimoto, T; Matsunaga, T; Shigetomi, M; Sugiyama, T; Suzuki, H; Taguchi, T; Tanaka, H1
Bilezikian, JP; Borba, VZ; Kulak, CA; Paz-Filho, G; Seibel, MJ1
Armstrong, A; Branstetter, D; Bussiere, J; Cowan, L; Dougall, WC; Jones, J; Kennedy, B; Miller, RE1
Kim, HW; Lee, JI1
Fratto, E; Galluzzo, S; Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B1
Robb-Nicholson, C1
Eagleton, MC; Hirbe, AC; Morgan, EA; Piwnica-Worms, D; Prior, JL; Rubin, J; Uluçkan, O; Weilbaecher, KN1
Auriola, S; Holen, I; Kuokkanen, J; Mönkkönen, H; Mönkkönen, J; Ottewell, PD1
Arlen, PM; Dahut, WL; Gulley, JL; Wu, S1
Suzuki, Y1
Bundred, N; Hadji, P1
Bateman, TA; Lloyd, SA; Lu, T; Travis, ND1
McKeage, K; Plosker, GL1
Brufsky, AM2
Brouwers, JE; Gasser, JA; Huiskes, R; Lambers, FM; van Rietbergen, B1
Dhillon, S; Lyseng-Williamson, KA1
Dai, R; Guo, H; Li, S; Liao, E; Liu, J; Sheng, Z; Wen, G; Wu, X; Xu, K1
Bagan, JV; Gómez, D; Jiménez, Y; Poveda, R; Scully, C; Sirera, R1
Arshad, MD; Bouler, JM; Bujoli, B; Faucheux, C; Guicheux, J; Janvier, P; Josse, S; Pilet, P; Soueidan, A; Verron, E1
Brown, JE; Coleman, RE; Cook, R; Garnero, P; Lipton, A; Major, P; Saad, F; Terpos, E1
Dai, RC; Jiang, YB; Liao, EY; Liu, JH; Ma, YL; Sheng, ZF; Xu, K; Zhang, YH1
Braidman, IP; Evans, CE1
Green, JR; Jaeggi, KA; Müller, K1
Green, J1
Arden-Cordone, M; Knieriem, A; Lyles, KW; Newton, RA; Schaffer, V; Siris, ES; Zelenakas, K1
Ziegler, J1
Binkley, N; Bruner, J; Davidowitz, B; Green, J; Haffa, A; Kimmel, D; Meng, C; Schaffer, V1
Birbara, CA; Buckler, H; Davie, M; Fogelman, I; Fraser, W; Hosking, D; Lyles, K; Maricic, MJ; Moses, AM; Richardson, P; Ryan, W; Seaman, J; Selby, P; Singer, F; Siris, E; Zelenakas, K1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP1
Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N1
Berenson, JR; Conde, F; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Vescio, R; Von Teichert, JM1
Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ1
Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M1
Cheer, SM; Noble, S1

Reviews

55 review(s) available for zoledronic acid and Bone Loss, Osteoclastic

ArticleYear
Bisphosphonate-loaded bone cement: Background, clinical indications and future perspectives.
    Journal of musculoskeletal & neuronal interactions, 2022, 12-01, Volume: 22, Issue:4

    Topics: Bone Cements; Bone Resorption; Diphosphonates; Humans; Orthopedic Procedures; Zoledronic Acid

2022
Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Life sciences, 2021, Jan-01, Volume: 264

    Topics: Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Humans; Osteoporosis; Treatment Outcome; Zoledronic Acid

2021
Therapeutic approaches for protecting bone health in patients with breast cancer.
    Breast (Edinburgh, Scotland), 2018, Volume: 37

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Practice Guidelines as Topic; Spinal Cord Compression; Zoledronic Acid

2018
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    Cancer treatment reviews, 2019, Volume: 76

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid

2019
[Biomarkers of bone remodelling].
    Bulletin du cancer, 2013, Volume: 100, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Humans; Imidazoles; Predictive Value of Tests; Zoledronic Acid

2013
Male hypogonadism and skeletal health.
    Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:6

    Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Denosumab; Diphosphonates; Humans; Hypogonadism; Imidazoles; Immunologic Factors; Klinefelter Syndrome; Male; Men's Health; Osteoporosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Testosterone; Zoledronic Acid

2013
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
    Cancer treatment reviews, 2015, Volume: 41, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid

2015
[Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
    Clinical calcium, 2008, Volume: 18, Issue:10

    Topics: Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Design; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Indoles; Organometallic Compounds; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Zoledronic Acid

2008
[Update on treatment of postmenopausal osteoporosis].
    Revue medicale de Bruxelles, 2008, Volume: 29, Issue:4

    Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid

2008
Bisphosphonates in breast cancer: teaching an old dog new tricks.
    Current opinion in oncology, 2009, Volume: 21, Issue:6

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Treatment Outcome; Zoledronic Acid

2009
Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
    Critical reviews in oncology/hematology, 2011, Volume: 79, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Injections, Intravenous; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid

2011
Managing bone health with zoledronic acid: a review of randomized clinical study results.
    Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Zoledronic Acid

2011
The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1

    Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imidazoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Osteoclasts; Zoledronic Acid

2011
New developments for treatment and prevention of bone metastases.
    Current opinion in oncology, 2011, Volume: 23, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid

2011
New role for an established drug? Bisphosphonates as potential anticancer agents.
    Prostate cancer and prostatic diseases, 2012, Volume: 15, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteoclasts; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid

2012
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
    Current osteoporosis reports, 2012, Volume: 10, Issue:1

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid

2012
Novel approaches to the management of bone metastases in patients with breast cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11

    Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid

2002
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    The oncologist, 2002, Volume: 7, Issue:6

    Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pamidronate; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid

2002
Advances in the biology and treatment of myeloma bone disease.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17

    Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid

2002
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Drugs, 2003, Volume: 63, Issue:4

    Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Humans; Hypercalcemia; Imidazoles; Kidney; Zoledronic Acid

2003
Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
    American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1

    Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid

2002
Preclinical pharmacology of zoledronic acid.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21

    Topics: Animals; Bone Density; Bone Neoplasms; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Humans; Imidazoles; Zoledronic Acid

2002
Treatment of hypercalcemia of malignancy with bisphosphonates.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21

    Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid

2002
Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21

    Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid

2002
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21

    Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid

2002
The anti-tumor potential of zoledronic acid.
    Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2

    Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Male; Mice; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Zoledronic Acid

2003
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
    Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2

    Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteolysis; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid

2003
Zoledronic acid: a review of its use in patients with advanced cancer.
    Drugs, 2004, Volume: 64, Issue:11

    Topics: Area Under Curve; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Drug Tolerance; Economics, Pharmaceutical; Female; Half-Life; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid

2004
Bisphosphonates: environmental protection for the joint?
    Arthritis and rheumatism, 2004, Volume: 50, Issue:7

    Topics: Animals; Arthritis; Arthritis, Rheumatoid; Bone Resorption; Collagen; Diphosphonates; Disease Progression; Imidazoles; Osteoclasts; Zoledronic Acid

2004
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 2

    Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid

2004
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 12

    Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid

2004
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
    Clinical breast cancer, 2005, Volume: 5 Suppl, Issue:2

    Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid

2005
New therapeutic agents for the treatment of bone diseases.
    Expert opinion on biological therapy, 2005, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid

2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    BJU international, 2005, Volume: 96, Issue:7

    Topics: Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Pain; Prostatic Neoplasms; Zoledronic Acid

2005
[Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 126, Issue:5

    Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Cells, Cultured; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Geranyltranstransferase; Humans; Hypercalcemia; Imidazoles; Neoplasms; Osteoclasts; Zoledronic Acid

2005
Pharmacological therapy of Paget's and other metabolic bone diseases.
    Bone, 2006, Volume: 38, Issue:2 Suppl 2

    Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Osteogenesis; Risedronic Acid; Zoledronic Acid

2006
Zoledronic acid: past, present and future roles in cancer treatment.
    Future oncology (London, England), 2005, Volume: 1, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Zoledronic Acid

2005
[Bisphosphonates for bone metastasis of malignant tumor].
    Clinical calcium, 2006, Volume: 16, Issue:4

    Topics: Bone Neoplasms; Bone Resorption; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Membrane Glycoproteins; Osteoclasts; Pain; Quality of Life; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid

2006
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Seminars in oncology, 2006, Volume: 33, Issue:2 Suppl 7

    Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid

2006
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pamidronate; Remission Induction; Treatment Outcome; Zoledronic Acid

2006
[Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
    Clinical calcium, 2007, Volume: 17, Issue:1

    Topics: Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoporosis, Postmenopausal; Zoledronic Acid

2007
[Molecular mechanism and potential targets for bone metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Osteolysis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid

2007
New developments of aminobisphosphonates: the double face of Janus.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 6

    Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Zoledronic Acid

2007
Reducing the risk of bone loss associated with breast cancer treatment.
    Breast (Edinburgh, Scotland), 2007, Volume: 16 Suppl 3

    Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Women's Health; Zoledronic Acid

2007
[Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
    Clinical calcium, 2007, Volume: 17, Issue:12

    Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Methotrexate; Osteoclasts; Zoledronic Acid

2007
New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
    Cancer treatment reviews, 2008, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid

2008
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Seminars in oncology, 2007, Volume: 34, Issue:6 Suppl 4

    Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Zoledronic Acid

2007
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    PharmacoEconomics, 2008, Volume: 26, Issue:3

    Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid

2008
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
    Clinical breast cancer, 2007, Volume: 8 Suppl 1

    Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasm Staging; Neoplasms, Hormone-Dependent; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid

2007
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    The oncologist, 2008, Volume: 13, Issue:2

    Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid

2008
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Drugs, 2008, Volume: 68, Issue:4

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid

2008
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
    Cancer, 2000, Jan-01, Volume: 88, Issue:1

    Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid

2000
Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.
    Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 6

    Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Humans; Imidazoles; Models, Animal; Osteoporosis; Zoledronic Acid

2001
Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
    Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 6

    Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid

2001
Zoledronic acid.
    Drugs, 2001, Volume: 61, Issue:6

    Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Neoplasms; Zoledronic Acid

2001

Trials

49 trial(s) available for zoledronic acid and Bone Loss, Osteoclastic

ArticleYear
Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:3

    Topics: Biomarkers; Bone Density; Bone Resorption; Denosumab; Humans; Osteoclasts; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2023
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:12

    Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Female; Femur Neck; Fractures, Bone; Humans; Middle Aged; Withholding Treatment; Zoledronic Acid

2019
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:5

    Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Female; Humans; Lumbar Vertebrae; Male; Osteoporosis; Osteoporotic Fractures; Risk Factors; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2021
Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:5

    Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lumbar Vertebrae; Male; Models, Biological; Osteoporosis; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2018
Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
    Bone, 2018, Volume: 114

    Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Premenopause; Prospective Studies; Time Factors; Treatment Outcome; Young Adult; Zoledronic Acid

2018
A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.
    Journal of the American Society of Nephrology : JASN, 2019, Volume: 30, Issue:2

    Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Female; Humans; Kidney Transplantation; Male; Postoperative Complications; Prospective Studies; Zoledronic Acid

2019
Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019, Volume: 30, Issue:8

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcitriol; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Hip Prosthesis; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postoperative Care; Single-Blind Method; Zoledronic Acid

2019
Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Aged; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Regeneration; Bone Resorption; Calcium Carbonate; Cholecalciferol; Collagen Type I; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Genetic Markers; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; PAX5 Transcription Factor; Peptides; Time Factors; Zoledronic Acid

2013
Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:1

    Topics: Aged; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Hip; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Spine; Zoledronic Acid

2014
Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:9

    Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Transplantation, Homologous; Treatment Outcome; Young Adult; Zoledronic Acid

2013
Identification of the risk factors associated with hypocalcemia induced by denosumab.
    Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Calcium; Creatinine; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteoclasts; RANK Ligand; Retrospective Studies; Risk Factors; ROC Curve; Zoledronic Acid

2013
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid

2014
Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:6

    Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Foot Bones; Gout; Humans; Imidazoles; Male; Middle Aged; Spine; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid

2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid

2014
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis.
    Journal of bone and mineral metabolism, 2017, Volume: 35, Issue:6

    Topics: Aged; Asian People; Biomarkers; Body Temperature; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteogenesis; Osteoporosis; Single-Blind Method; Zoledronic Acid

2017
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
    Journal of clinical pathology, 2009, Volume: 62, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid

2009
Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:1

    Topics: Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Osteoporosis; Spinal Cord Injuries; Young Adult; Zoledronic Acid

2011
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid

2010
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2010, Volume: 25, Issue:10

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Placebos; Postmenopause; Zoledronic Acid

2010
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:11

    Topics: Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Databases as Topic; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Osteonecrosis; Osteoporosis, Postmenopausal; Peptides; Placebos; Prevalence; Risk Factors; United States; Zoledronic Acid

2010
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
    Bone, 2011, Volume: 49, Issue:1

    Topics: Acute-Phase Reaction; Anticholesteremic Agents; Bone Density Conservation Agents; Bone Resorption; Cholesterol; Cytokines; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Imidazoles; Indoles; Injections, Intravenous; Middle Aged; Postmenopause; T-Lymphocytes; Zoledronic Acid

2011
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
    Clinical breast cancer, 2010, Dec-01, Volume: 10, Issue:6

    Topics: Adult; Biomarkers; Biphenyl Compounds; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cathepsin K; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid

2010
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid

2011
Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Nasopharyngeal Neoplasms; Peptides; Treatment Outcome; Zoledronic Acid

2011
Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
    Bone, 2012, Volume: 50, Issue:6

    Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Peptide Fragments; Peptides; Procollagen; Time Factors; Zoledronic Acid

2012
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:12

    Topics: Adult; Alendronate; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Heart Transplantation; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Placebos; Postoperative Care; Postoperative Complications; Zoledronic Acid

2012
No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial.
    Calcified tissue international, 2013, Volume: 92, Issue:1

    Topics: Acid Phosphatase; Aged; Bone Density Conservation Agents; Bone Resorption; CD11b Antigen; Diphosphonates; Female; Flow Cytometry; Humans; Imidazoles; Isoenzymes; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Middle Aged; Osteoclasts; Osteoporosis; Placebos; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2013
Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial.
    The Journal of arthroplasty, 2013, Volume: 28, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Imidazoles; Male; Middle Aged; Postoperative Complications; Prospective Studies; Time Factors; Zoledronic Acid

2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Lymphoma; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult; Zoledronic Acid

2013
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Journal of the National Cancer Institute, 2002, Oct-02, Volume: 94, Issue:19

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid

2002
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21

    Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid

2002
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Urology, 2004, Volume: 63, Issue:5

    Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid

2004
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 2

    Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid

2004
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    The oncologist, 2004, Volume: 9, Issue:6

    Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid

2004
Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:3

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid

2005
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
    Oncology, 2005, Volume: 69, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cytokines; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Interferon-gamma; Interleukins; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Metalloproteases; Middle Aged; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Zoledronic Acid

2005
CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Breast Neoplasms; Clinical Protocols; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Zoledronic Acid

2005
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Urology, 2005, Volume: 66, Issue:5

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid

2005
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:5

    Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Zoledronic Acid

2005
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Pain; Peptides; Thalidomide; Treatment Outcome; Zoledronic Acid

2006
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.
    Haematologica, 2006, Volume: 91, Issue:9

    Topics: beta-Thalassemia; Bone Density; Bone Resorption; Diphosphonates; Humans; Imidazoles; Osteoporosis; Placebos; Treatment Outcome; Zoledronic Acid

2006
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Bone, 2007, Volume: 40, Issue:5

    Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Peptides; Postmenopause; Surveys and Questionnaires; Time Factors; Zoledronic Acid

2007
A single infusion of zoledronate prevents bone loss after stroke.
    Stroke, 2007, Volume: 38, Issue:5

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Hemiplegia; Humans; Imidazoles; Male; Middle Aged; Stroke; Zoledronic Acid

2007
Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
    Calcified tissue international, 2007, Volume: 80, Issue:5

    Topics: Adolescent; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Femur Neck; Humans; Imidazoles; Male; Spinal Cord Injuries; Zoledronic Acid

2007
Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Calcified tissue international, 1997, Volume: 60, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Resorption; Calcium; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hydroxyproline; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Zoledronic Acid

1997
Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.
    Bone, 1999, Volume: 24, Issue:5 Suppl

    Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hydroxyproline; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Zoledronic Acid

1999
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Cancer, 2001, Jan-01, Volume: 91, Issue:1

    Topics: Adult; Aged; Anorexia; Biomarkers; Bone Neoplasms; Bone Resorption; Constipation; Diphosphonates; Female; Fever; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid

2001
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Cancer, 2001, Apr-01, Volume: 91, Issue:7

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid

2001
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:3

    Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors; Zoledronic Acid

2001

Other Studies

157 other study(ies) available for zoledronic acid and Bone Loss, Osteoclastic

ArticleYear
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
    Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14

    Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats

2002
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
    Journal of medicinal chemistry, 2002, Aug-15, Volume: 45, Issue:17

    Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid

2002
A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
    Journal of medicinal chemistry, 2003, Jul-03, Volume: 46, Issue:14

    Topics: Alendronate; Bone Resorption; Diphosphonates; Heterocyclic Compounds; Models, Molecular; Pamidronate; Quantitative Structure-Activity Relationship

2003
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
    Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8

    Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents

2005
Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in Ovariectomized Mice without Affecting Bone Formation.
    Journal of medicinal chemistry, 2020, 11-25, Volume: 63, Issue:22

    Topics: Alkanes; Animals; Bone Resorption; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Ovariectomy

2020
Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.
    Molecular medicine reports, 2022, Volume: 25, Issue:2

    Topics: Animals; Bone Density; Bone Resorption; Cell Differentiation; Gene Expression Regulation; MAP Kinase Kinase 4; Mice; NF-kappa B; NFATC Transcription Factors; Osteogenesis; Phosphorylation; RANK Ligand; RAW 264.7 Cells; Signal Transduction; Zoledronic Acid

2022
Effects of Anti-Receptor Activator of Nuclear Factor Kappa B Ligand Antibody and Zoledronic Acid on Periapical Lesion Development in Mice.
    Journal of endodontics, 2022, Volume: 48, Issue:5

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Inflammation; Mice; NF-kappa B; Osteoclasts; RANK Ligand; Zoledronic Acid

2022
Inhibition of osteoclastogenesis after bisphosphonate therapy discontinuation: an in vitro approach.
    Journal of molecular histology, 2022, Volume: 53, Issue:4

    Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Mice; Osteoclasts; Osteogenesis; Zoledronic Acid

2022
Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption.
    PloS one, 2022, Volume: 17, Issue:7

    Topics: Animals; Bone Resorption; Cartilage, Articular; Disease Models, Animal; Male; Osteoarthritis; Rats; Wnt-5a Protein; X-Ray Microtomography; Zoledronic Acid

2022
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
    Biomaterials science, 2022, Oct-11, Volume: 10, Issue:20

    Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid

2022
Effect of oral zoledronate administration on bone turnover in older women.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:3

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid

2023
The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis.
    Biomaterials, 2023, Volume: 296

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Mice; Osteoclasts; Osteoporosis; Zoledronic Acid

2023
A Dual-Targeted Metal-Organic Framework Based Nanoplatform for the Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche.
    ACS nano, 2023, 07-25, Volume: 17, Issue:14

    Topics: Arthritis, Rheumatoid; Bone Resorption; Delayed-Action Preparations; Humans; Macrophages; Metal-Organic Frameworks; Osteoclasts; Zoledronic Acid

2023
A Machine Learning-Based Image Segmentation Method to Quantify In Vitro Osteoclast Culture Endpoints.
    Calcified tissue international, 2023, Volume: 113, Issue:4

    Topics: Acid Phosphatase; Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Coculture Techniques; Mice; Osteoclasts; Tartrate-Resistant Acid Phosphatase; Ticagrelor; Zoledronic Acid

2023
Zoledronic acid epigenetically alleviates high-glucose-suppressed osteogenic differentiation of MC3T3-E1 cells.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:16

    Topics: Bone Resorption; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Epigenesis, Genetic; Glucose; Humans; MicroRNAs; Osteogenesis; Osteoporosis; RNA, Long Noncoding; Zoledronic Acid

2023
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
    Endocrine journal, 2020, Jan-28, Volume: 67, Issue:1

    Topics: Ankle; Anorexia; Antithyroid Agents; Aromatase Inhibitors; Arthralgia; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen Type I; Denosumab; Deprescriptions; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Graves Disease; Humans; Hypercalcemia; Methimazole; Middle Aged; Parathyroid Hormone; Peptides; Potassium Iodide; Radionuclide Imaging; Tartrate-Resistant Acid Phosphatase; Thirst; Zoledronic Acid

2020
Nanohydroxyapatite Based Ceramic Carrier Promotes Bone Formation in a Femoral Neck Canal Defect in Osteoporotic Rats.
    Biomacromolecules, 2020, 02-10, Volume: 21, Issue:2

    Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Bone Resorption; Calcium Sulfate; Drug Carriers; Exosomes; Female; Femur Neck; Hip Fractures; Hydroxyapatites; Nanostructures; Osteogenesis; Osteoporosis; Rats, Sprague-Dawley; Recombinant Proteins; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid

2020
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
    International journal of cancer, 2020, 06-15, Volume: 146, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Denosumab; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peptides; Prognosis; Prospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2020
Modulation of bone formation and resorption using a novel zoledronic acid loaded gelatin nanoparticles integrated porous titanium scaffold: an in vitro and in vivo study.
    Biomedical materials (Bristol, England), 2020, 07-27, Volume: 15, Issue:5

    Topics: Animals; Biocompatible Materials; Bone and Bones; Bone Regeneration; Bone Resorption; Cell Adhesion; Cell Differentiation; Cell Proliferation; Female; Gelatin; In Vitro Techniques; Nanoparticles; Osteoclasts; Osteogenesis; Osteoporosis; Porosity; Rabbits; Static Electricity; Tissue Scaffolds; Titanium; Zoledronic Acid

2020
Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.
    Bone, 2020, Volume: 138

    Topics: Bone Resorption; CTLA-4 Antigen; Diphosphonates; Female; Humans; Imidazoles; Leukocytes, Mononuclear; Zoledronic Acid

2020
[Zoledronate regulates osteoclast differentiation and bone resorption in high glucose through p38 MAPK pathway].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020, Oct-30, Volume: 40, Issue:10

    Topics: Animals; Bone Resorption; Cell Differentiation; Glucose; MAP Kinase Signaling System; Mice; NFATC Transcription Factors; Osteoclasts; p38 Mitogen-Activated Protein Kinases; RANK Ligand; Zoledronic Acid

2020
The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats.
    Scientific reports, 2021, 04-07, Volume: 11, Issue:1

    Topics: Alveolar Process; Animals; Bone Density Conservation Agents; Bone Resorption; Drug Evaluation, Preclinical; Male; Osteoporosis; Periodontal Ligament; Rats, Wistar; Tooth Movement Techniques; Tooth Root; Zoledronic Acid

2021
Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats.
    Experimental biology and medicine (Maywood, N.J.), 2021, Volume: 246, Issue:15

    Topics: Animals; Apoptosis; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cell Differentiation; Female; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Rats, Sprague-Dawley; Signal Transduction; Zoledronic Acid

2021
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7

    Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Deprescriptions; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Time Factors; Treatment Failure; Zoledronic Acid

2017
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
    Endocrinology, 2017, 09-01, Volume: 158, Issue:9

    Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Knockout; Nuclear Matrix-Associated Proteins; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Transcription Factors; Zoledronic Acid

2017
Long-term therapy with intravenous zoledronate increases the number of nonattached osteoclasts.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2017, Volume: 45, Issue:11

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Count; Diphosphonates; Imidazoles; Immunohistochemistry; Injections, Intravenous; Male; Osteoclasts; Osteogenesis; Osteoprotegerin; RANK Ligand; Rats; Tooth Extraction; Tooth Socket; Wound Healing; Zoledronic Acid

2017
Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: An in vitro and in vivo study.
    Acta biomaterialia, 2018, Volume: 65

    Topics: Absorbable Implants; Alloys; Animals; Biocompatible Materials; Bone Development; Bone Nails; Bone Resorption; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Femoral Fractures; Fracture Healing; Imidazoles; Magnesium; Mesenchymal Stem Cells; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Osteoporotic Fractures; Rats, Sprague-Dawley; Zoledronic Acid

2018
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model.
    BMC musculoskeletal disorders, 2017, Nov-13, Volume: 18, Issue:1

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Fibrosis; Imidazoles; Prosthesis Failure; Sheep; Zoledronic Acid

2017
In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Pathology oncology research : POR, 2019, Volume: 25, Issue:1

    Topics: Adult; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Proliferation; Denosumab; Giant Cell Tumor of Bone; Humans; In Vitro Techniques; Male; Middle Aged; Osteoclasts; Prognosis; Tumor Cells, Cultured; Zoledronic Acid

2019
Simple 3,4-Dihydroxy-L-Phenylalanine Surface Modification Enhances Titanium Implant Osseointegration in Ovariectomized Rats.
    Scientific reports, 2017, 12-19, Volume: 7, Issue:1

    Topics: Animals; Bone Resorption; Bone-Anchored Prosthesis; Cell Differentiation; Coated Materials, Biocompatible; Dental Implantation, Endosseous; Dental Implants; Dental Prosthesis Design; Diphosphonates; Female; Osseointegration; Osteoclasts; Osteoporosis; Ovariectomy; Phenylalanine; Rats; Rats, Sprague-Dawley; Surface Properties; Titanium; Torque; X-Ray Microtomography; Zoledronic Acid

2017
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis.
    Bone, 2018, Volume: 108

    Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Body Weight; Bone Resorption; Dose-Response Relationship, Drug; Female; Femur; Osteocytes; Periodontitis; Prevalence; Sigmodontinae; Treatment Outcome; Zoledronic Acid

2018
[Experimental study on inhibitory effect of zoledronic acid on the action style of the osteoclast].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2017, Volume: 34, Issue:1

    Topics: Acid Phosphatase; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cells, Cultured; Mice; Osteoclasts; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2017
New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Leukemia, 2018, Volume: 32, Issue:11

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Line; HEK293 Cells; Hematopoiesis; Humans; Lymphopoiesis; Mice; Mice, Inbred C57BL; Osteoclasts; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RANK Ligand; Tumor Microenvironment; Zoledronic Acid

2018
Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62
    Disease models & mechanisms, 2018, 08-23, Volume: 11, Issue:9

    Topics: Aging; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Disease Models, Animal; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Organ Size; Osteitis Deformans; Osteoclasts; Phenotype; Sequestosome-1 Protein; Zoledronic Acid

2018
Zoledronic acid : Treatment option for Gorham-Stout disease.
    Der Orthopade, 2018, Volume: 47, Issue:12

    Topics: Biopsy; Bone Resorption; Female; Humans; Middle Aged; Osteolysis, Essential; Treatment Outcome; Vitamin D; Zoledronic Acid

2018
Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway.
    Biochemical and biophysical research communications, 2018, 11-10, Volume: 505, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Movement; Cell Survival; Glucose; Mice; Osteoclasts; RAW 264.7 Cells; Signal Transduction; Zoledronic Acid

2018
Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.
    BMC musculoskeletal disorders, 2018, Nov-30, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Asian People; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Denosumab; Female; Follow-Up Studies; Hong Kong; Humans; Incidence; Mastectomy; Middle Aged; Postmenopause; Radiotherapy, Adjuvant; Receptors, Estrogen; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid

2018
Contribution of Inflammation and Bone Destruction to Pain in Arthritis: A Study in Murine Glucose-6-Phosphate Isomerase-Induced Arthritis.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:12

    Topics: Activating Transcription Factor 3; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Resorption; Cyclic AMP Response Element-Binding Protein; Glucose-6-Phosphate Isomerase; Hindlimb; Hyperalgesia; Inflammation; Mice; Pain; T-Lymphocytes, Regulatory; TRPV Cation Channels; Zoledronic Acid

2019
Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Cell Adhesion Molecules; Diphosphonates; Female; Imidazoles; Jaw; Mice; Mice, Knockout; Ovariectomy; Tomography, X-Ray Computed; Zoledronic Acid

2013
Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
    Veterinary and comparative oncology, 2015, Volume: 13, Issue:3

    Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cat Diseases; Cats; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diphosphonates; Disease Models, Animal; Heterografts; Humans; Imidazoles; Male; Meloxicam; Mice; Mice, Nude; Mouth Neoplasms; Neoplasms, Squamous Cell; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thiazines; Thiazoles; Treatment Outcome; Zoledronic Acid

2015
Zoledronic acid prevents loss of trabecular bone after focal irradiation in mice.
    Radiation research, 2013, Volume: 180, Issue:1

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Mice; Radiation-Protective Agents; Radiotherapy; X-Rays; Zoledronic Acid

2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.
    Wiener klinische Wochenschrift, 2013, Volume: 125, Issue:15-16

    Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Internationality; Palliative Care; Treatment Outcome; Zoledronic Acid

2013
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid

2013
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
    Oncology reports, 2013, Volume: 30, Issue:6

    Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Immunohistochemistry; Integrins; Jaw; Microscopy, Electron, Scanning; Mouth Mucosa; Osteonecrosis; Pamidronate; Sarcoglycans; Zoledronic Acid

2013
Preclinical evaluation of zoledronate to maintain bone allograft and improve implant fixation in revision joint replacement.
    The Journal of bone and joint surgery. American volume, 2013, Oct-16, Volume: 95, Issue:20

    Topics: Animals; Arthroplasty, Replacement, Knee; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Diphosphonates; Dogs; Female; Imidazoles; Knee Prosthesis; Postoperative Complications; Random Allocation; Reoperation; Transplantation, Homologous; Treatment Outcome; Zoledronic Acid

2013
Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
    The Tohoku journal of experimental medicine, 2013, Volume: 231, Issue:2

    Topics: Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Foscarnet; Imidazoles; Mice; Mice, Inbred BALB C; Molecular Structure; Necrosis; Osteitis; Phosphate Transport Proteins; Zoledronic Acid

2013
Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2014, Volume: 42, Issue:6

    Topics: Abscess; Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Imidazoles; Injections, Intraperitoneal; Injections, Intravenous; Male; Maxilla; Molar; Osteoclasts; Osteosclerosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid

2014
Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
    Biochimica et biophysica acta, 2014, Apr-04, Volume: 1841, Issue:4

    Topics: Bone Resorption; Diphosphonates; Gene Expression Regulation; Geranyltranstransferase; HeLa Cells; Humans; Imidazoles; Osteoclasts; Protein Prenylation; Sterol Regulatory Element Binding Protein 1; Zoledronic Acid

2014
Effect of bisphosphonates on the rapidly growing male murine skeleton.
    Endocrinology, 2014, Volume: 155, Issue:4

    Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Chondrocytes; Clodronic Acid; Diphosphonates; Hypertrophy; Imidazoles; Male; Mice; Mice, Inbred C57BL; Pamidronate; Phenotype; X-Ray Microtomography; Zoledronic Acid

2014
Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014, Volume: 29, Issue:6

    Topics: Animals; Bone Resorption; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Diphosphonates; Humans; Imidazoles; Mice; Monocytes; Neoplasm Invasiveness; Osteoclasts; Osteogenesis; Osteolysis; Osteoprotegerin; Osteosarcoma; RANK Ligand; Zoledronic Acid

2014
Early tissue responses to zoledronate, locally delivered by bone screw, into a compromised cancellous bone site: a pilot study.
    BMC musculoskeletal disorders, 2014, Mar-23, Volume: 15

    Topics: Animals; Bone Resorption; Bone Screws; Coated Materials, Biocompatible; Diphosphonates; Drug Evaluation, Preclinical; Exudates and Transudates; Femur; Fibrin; Fibrinogen; Fibrosis; Imidazoles; Implants, Experimental; Macrophages; Male; Mesoderm; Osseointegration; Osteoclasts; Pilot Projects; Rabbits; Titanium; Zoledronic Acid

2014
Mesoporous silica nanoparticles/hydroxyapatite composite coated implants to locally inhibit osteoclastic activity.
    ACS applied materials & interfaces, 2014, Apr-23, Volume: 6, Issue:8

    Topics: Animals; Bone Resorption; Bone Wires; Coated Materials, Biocompatible; Diphosphonates; Drug Carriers; Durapatite; Humans; Imidazoles; Nanoparticles; Osteoclasts; Porosity; Prostheses and Implants; Silicon Dioxide; Zoledronic Acid

2014
Maximizing bone formation in posterior spine fusion using rhBMP-2 and zoledronic acid in wild type and NF1 deficient mice.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2014, Volume: 32, Issue:8

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Knockout; Neurofibromatosis 1; Neurofibromin 1; Osteogenesis; Pseudarthrosis; Recombinant Proteins; Spinal Fusion; X-Ray Microtomography; Zoledronic Acid

2014
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:3

    Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness Research; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Propensity Score; Proportional Hazards Models; Registries; Survival Rate; Veterans; Zoledronic Acid

2015
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Cytokines; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteonecrosis; Pamidronate; Peptides; Prognosis; Zoledronic Acid

2014
[The rescue effect of RANKL on zoledronate induced acid inhibition of osteoclastogenesis and gene expression of NF-kappaB p50 and c-Jun].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2014, Volume: 31, Issue:2

    Topics: Animals; Bone Resorption; Cell Line; Diphosphonates; Gene Expression; Imidazoles; Mice; NF-kappa B p50 Subunit; Osteoblasts; Osteoclasts; Proto-Oncogene Proteins c-jun; RANK Ligand; Zoledronic Acid

2014
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.
    Endocrine-related cancer, 2014, Volume: 21, Issue:5

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Male; Mice, Inbred BALB C; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid

2014
Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
    Bone, 2014, Volume: 68

    Topics: Acid Phosphatase; Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Male; Maxilla; Mice, Inbred C57BL; Periodontium; Radiography; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2014
Osteoclast inhibition impairs chondrosarcoma growth and bone destruction.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2014, Volume: 32, Issue:12

    Topics: Animals; Bone and Bones; Bone Resorption; Chondrosarcoma; Diphosphonates; Imidazoles; Male; Osteoclasts; Parathyroid Hormone-Related Protein; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta2; Zoledronic Acid

2014
Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.
    The American journal of pathology, 2014, Volume: 184, Issue:11

    Topics: Animals; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Denosumab; Diphosphonates; Disease Models, Animal; Imidazoles; Mice; Osteoclasts; RANK Ligand; Zoledronic Acid

2014
Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.
    Endocrine-related cancer, 2014, Volume: 21, Issue:5

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid

2014
Does locally delivered Zoledronate influence peri-implant bone formation? - Spatio-temporal monitoring of bone remodeling in vivo.
    Biomaterials, 2014, Volume: 35, Issue:37

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Bone Screws; Diphosphonates; Drug Delivery Systems; Female; Femur; Hydrogel, Polyethylene Glycol Dimethacrylate; Imidazoles; Osteogenesis; Rats; Zoledronic Acid

2014
[Zoledronate inhibits TRPV5 and NFATc1 expression during differentiation of osteoclasts].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2014, Volume: 34, Issue:9

    Topics: Animals; Bone Resorption; Calcium Channels; Cell Differentiation; Cell Line; Diphosphonates; Down-Regulation; Imidazoles; Mice; NFATC Transcription Factors; Osteoclasts; RANK Ligand; RNA, Messenger; TRPV Cation Channels; Zoledronic Acid

2014
Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015, Volume: 30, Issue:5

    Topics: Animals; Antineoplastic Agents; Bone Density; Bone Remodeling; Bone Resorption; Chemokine CCL2; Cytokines; Diphosphonates; Hematopoiesis; Imidazoles; Inflammation; Inflammation Mediators; Mice, Inbred C57BL; Stem Cell Transplantation; Transplantation, Homologous; X-Ray Microtomography; Zoledronic Acid

2015
Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:11

    Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cell Differentiation; Collagen Type I; Denosumab; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Peptides; RANK Ligand; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2014
[Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].
    Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology, 2014, Volume: 32, Issue:6

    Topics: Animals; Bone Resorption; Diphosphonates; Gene Expression; Imidazoles; Integrin alphaV; Mice; Osteoclasts; RNA, Messenger; Zoledronic Acid

2014
OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015, Volume: 30, Issue:9

    Topics: Abscess; Acid Phosphatase; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Resorption; Denosumab; Diphosphonates; Disease Models, Animal; Imidazoles; Immunoglobulin Fc Fragments; Isoenzymes; Male; Mandible; Maxilla; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; RANK Ligand; Rats; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography; Zoledronic Acid

2015
Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats.
    Journal of endodontics, 2015, Volume: 41, Issue:12

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; Female; Imidazoles; Immunohistochemistry; Osteonecrosis; Ovariectomy; Periapical Periodontitis; Rats, Wistar; X-Ray Microtomography; Zoledronic Acid

2015
Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass.
    Acta biomaterialia, 2016, Volume: 31

    Topics: Animals; Apoptosis; Bone Resorption; Borates; Cell Differentiation; Diphosphonates; Glass; Imidazoles; Macrophages; Mice; Microscopy, Electron, Transmission; Nitrogen; Osteoclasts; Osteonecrosis; Oxidative Stress; RANK Ligand; RAW 264.7 Cells; Reactive Oxygen Species; Risedronic Acid; Water; Zoledronic Acid

2016
Zoledronate prevents lactation induced bone loss and results in additional post-lactation bone mass in mice.
    Bone, 2016, Volume: 87

    Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Female; Femur; Fractures, Bone; Imidazoles; Lactation; Mice; Organ Size; Osteogenesis; Tartrate-Resistant Acid Phosphatase; Weaning; X-Ray Microtomography; Zoledronic Acid

2016
Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid.
    Journal of human genetics, 2017, Volume: 62, Issue:2

    Topics: Adult; Asian People; Base Sequence; Bone Density; Bone Density Conservation Agents; Bone Resorption; Child; Child, Preschool; China; Collagen Type I; Collagen Type I, alpha 1 Chain; Diphosphonates; Female; Fractures, Bone; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Male; Membrane Proteins; Osteogenesis Imperfecta; Sequence Analysis, DNA; Tacrolimus Binding Proteins; Young Adult; Zoledronic Acid

2017
Effects of Bisphosphonate Administration on Cleft Bone Graft in a Rat Model.
    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association, 2017, Volume: 54, Issue:6

    Topics: Alveolar Process; Animals; Bone Resorption; Bone Transplantation; Diphosphonates; Female; Femur; Ilium; Imidazoles; Rats; Rats, Inbred F344; X-Ray Microtomography; Zoledronic Acid

2017
Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid.
    Scientific reports, 2017, 02-01, Volume: 7

    Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Count; Clomipramine; Diphosphonates; Imidazoles; Mice, Inbred C57BL; Organ Size; Osteoclasts; Osteogenesis; Osteoporosis; Ubiquitin-Protein Ligases; Zoledronic Acid

2017
Bisphosphonates in children with hypercalciuria and reduced bone mineral density.
    Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:12

    Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Child; Creatinine; Diphosphonates; Female; Humans; Hypercalciuria; Imidazoles; Male; Phosphorus; Retrospective Studies; Zoledronic Acid

2008
Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
    Journal of biomedical materials research. Part A, 2009, Volume: 91, Issue:1

    Topics: Acid Phosphatase; Bone Density Conservation Agents; Bone Resorption; Cell Count; Cells, Cultured; Coated Materials, Biocompatible; Coculture Techniques; Collagen Type I; Collagen Type I, alpha 1 Chain; Diphosphonates; Humans; Imidazoles; Isoenzymes; Osteoblasts; Osteoclasts; Osteoprotegerin; Polyesters; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2009
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
    Bone, 2009, Volume: 44, Issue:2

    Topics: Acid Phosphatase; Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Female; Humans; Imidazoles; Isoenzymes; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Osteolysis; Osteoprotegerin; Radiography; Tartrate-Resistant Acid Phosphatase; Whole Body Imaging; Zoledronic Acid

2009
A classical presentation of Paget disease of bone.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:6

    Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femur; Humans; Imidazoles; Male; Osteitis Deformans; Pelvis; Radiography; Zoledronic Acid

2008
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Journal of bone and mineral metabolism, 2009, Volume: 27, Issue:4

    Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Necrosis; Osteoclasts; Osteonecrosis; Thalidomide; Zoledronic Acid

2009
Zoledronate reduces unwanted bone resorption in intercalary bone allografts.
    International orthopaedics, 2010, Volume: 34, Issue:4

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bone Remodeling; Bone Resorption; Bone Transplantation; Diphosphonates; Disease Models, Animal; Femur; Graft Survival; Imidazoles; Male; Radiography; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Transplantation, Homologous; Zoledronic Acid

2010
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
    The American journal of pathology, 2009, Volume: 174, Issue:6

    Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid

2009
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
    International journal of cancer, 2010, Jul-15, Volume: 127, Issue:2

    Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Caspases; Cell Proliferation; Diphosphonates; Imidazoles; Lung Neoplasms; Male; Osteosarcoma; Rats; Rats, Inbred F344; Zoledronic Acid

2010
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5

    Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid

2010
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
    British journal of haematology, 2010, Volume: 151, Issue:1

    Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Zoledronic Acid

2010
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
    BMC cancer, 2010, Aug-29, Volume: 10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Osteoclasts; Treatment Outcome; Tumor Cells, Cultured; Young Adult; Zoledronic Acid

2010
Bisphosphonates and atypical femoral fractures.
    The New England journal of medicine, 2010, 09-09, Volume: 363, Issue:11

    Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteonecrosis; Risk Factors; Zoledronic Acid

2010
Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
    Cancer research, 2010, Nov-01, Volume: 70, Issue:21

    Topics: Acid Phosphatase; Animals; Bone Density Conservation Agents; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cats; Diphosphonates; Disease Models, Animal; Imidazoles; Isoenzymes; Luciferases; Male; Mice; Mice, Nude; Mouth Neoplasms; Osteoclasts; Osteolysis; Tartrate-Resistant Acid Phosphatase; Transplantation, Heterologous; X-Ray Microtomography; Zoledronic Acid

2010
The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis.
    Journal of biomechanics, 2011, Feb-03, Volume: 44, Issue:3

    Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Estrogens; Female; Imidazoles; Models, Animal; Osteoporosis; Ovariectomy; Sheep; Zoledronic Acid

2011
Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
    Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 383, Issue:3

    Topics: Acid Phosphatase; Animals; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cell Line, Tumor; Cell Movement; Diphosphonates; Diterpenes; Dose-Response Relationship, Drug; Gene Expression; I-kappa B Proteins; Imidazoles; Isoenzymes; Macrophages; Mice; Mice, Inbred Strains; NF-kappa B; NF-KappaB Inhibitor alpha; Osteoclasts; Phosphorylation; Protein Prenylation; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Stem Cells; Tartrate-Resistant Acid Phosphatase; Transcription, Genetic; Tumor Necrosis Factor-alpha; Up-Regulation; Zoledronic Acid

2011
[Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells].
    Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2011, Volume: 46, Issue:2

    Topics: Alkaline Phosphatase; Animals; Biocompatible Materials; Bone Density Conservation Agents; Bone Resorption; Cell Proliferation; Cells, Cultured; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Imidazoles; Membranes, Artificial; Osteoblasts; Osteoclasts; Osteogenesis; Rabbits; Zoledronic Acid

2011
Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.
    Blood, 2012, Jan-12, Volume: 119, Issue:2

    Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Bone Marrow; Bone Resorption; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chemokine CCL3; Diphosphonates; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hematopoiesis; Humans; Imidazoles; Immunocompetence; Immunoenzyme Techniques; Leukemia, Myeloid; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen; Zoledronic Acid

2012
In vitro generation of mature human osteoclasts.
    Calcified tissue international, 2011, Volume: 89, Issue:5

    Topics: Bone Resorption; Calcitonin; Diphosphonates; Humans; Imidazoles; Lipopolysaccharide Receptors; Microscopy, Phase-Contrast; Monocytes; Osteoclasts; Osteoprotegerin; Zoledronic Acid

2011
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
    Bone, 2012, Volume: 50, Issue:3

    Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Neurofibromatosis 1; Osteoclasts; Osteoporosis; Zoledronic Acid

2012
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:9

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blotting, Western; Bone Resorption; Breast Neoplasms; Cell Proliferation; Diphosphonates; Female; Fibronectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MCF-7 Cells; Microarray Analysis; Real-Time Polymerase Chain Reaction; Thrombospondin 1; Transforming Growth Factor beta1; Up-Regulation; Zoledronic Acid

2012
Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats.
    Biomedical materials (Bristol, England), 2012, Volume: 7, Issue:3

    Topics: Animals; Bone Cements; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphates; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Treatment Outcome; Zoledronic Acid

2012
Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:8

    Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Cell Culture Techniques; Cell Line; Cell Shape; Cell Survival; Collagen; Coloring Agents; Cytoprotection; Diphosphonates; Drug Carriers; Durapatite; Female; Fibroblasts; Fluoresceins; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Models, Animal; Osteoblasts; Osteogenesis; Protective Agents; Rabbits; Razoxane; Tetrazolium Salts; Thiazoles; Tibia; Zoledronic Acid

2012
Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.
    European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2012, Volume: 21 Suppl 1

    Topics: Adult; Aged; Bone Diseases; Bone Resorption; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pain Measurement; Positron-Emission Tomography; Quality of Life; Retrospective Studies; Spine; Treatment Outcome; Zoledronic Acid

2012
Marrow adiposity recovery after early zoledronic acid treatment of glucocorticoid-induced bone loss in rabbits assessed by magnetic resonance spectroscopy.
    Bone, 2013, Volume: 52, Issue:2

    Topics: Absorptiometry, Photon; Adipocytes; Adiposity; Animals; Body Weight; Bone Density; Bone Marrow; Bone Marrow Cells; Bone Resorption; Diphosphonates; Female; Femur; Glucocorticoids; Imidazoles; Lipids; Magnetic Resonance Spectroscopy; Rabbits; Reproducibility of Results; Zoledronic Acid

2013
Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats.
    BMC musculoskeletal disorders, 2012, Dec-05, Volume: 13

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diffusion Chambers, Culture; Diphosphonates; Female; Imidazoles; Male; Osteogenesis; Random Allocation; Rats; Tibia; Titanium; Transplantation, Homologous; Treatment Outcome; Zoledronic Acid

2012
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:4

    Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid

2013
New drugs 2002, part III.
    Nursing, 2002, Volume: 32, Issue:7

    Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid

2002
Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Calcified tissue international, 2003, Volume: 72, Issue:4

    Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femur; Humans; Imidazoles; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Weight-Bearing; Zoledronic Acid

2003
Zoledronate treatment in active Paget's disease.
    Annals of the rheumatic diseases, 2003, Volume: 62, Issue:3

    Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Osteitis Deformans; Zoledronic Acid

2003
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
    British journal of cancer, 2003, May-19, Volume: 88, Issue:10

    Topics: Bone Resorption; Breast Neoplasms; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Cyclooxygenase 2; Dinoprostone; Diphosphonates; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Osteolysis; Prostaglandin-Endoperoxide Synthases; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Zoledronic Acid

2003
Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis.
    The Annals of otology, rhinology, and laryngology, 2003, Volume: 112, Issue:9 Pt 1

    Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Division; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Imidazoles; Injections, Subcutaneous; Keratins; Male; Mice; Mice, Inbred C57BL; Minerals; Osteitis; Osteoclasts; Osteolysis; Parietal Bone; Periosteum; Prostheses and Implants; Skull; Zoledronic Acid

2003
Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    The Journal of urology, 2003, Volume: 170, Issue:6 Pt 1

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Resorption; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid

2003
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2003, Volume: 23, Issue:11

    Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; Fever; Humans; Imidazoles; Interferon-gamma; Interleukin-6; Male; Middle Aged; Tumor Necrosis Factor-alpha; Zoledronic Acid

2003
Severe hypocalcaemia after being given intravenous bisphosphonate.
    BMJ (Clinical research ed.), 2004, Feb-07, Volume: 328, Issue:7435

    Topics: Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid

2004
Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2004, Volume: 15, Issue:9

    Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Compressive Strength; Diphosphonates; Dose-Response Relationship, Drug; Estrogens; Female; Imidazoles; Lumbar Vertebrae; Osteocalcin; Ovariectomy; Rats; Rats, Sprague-Dawley; Time Factors; Tomography; Zoledronic Acid

2004
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004, Volume: 12, Issue:9

    Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Imidazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Pamidronate; Quality of Life; Recurrence; Zoledronic Acid

2004
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Arthritis; Arthrography; Bone and Bones; Bone Density; Bone Resorption; Calcitonin; Cartilage, Articular; Diphosphonates; Hindlimb; Humans; Imidazoles; Infliximab; Joints; Mice; Mice, Transgenic; Osteoclasts; Osteogenesis; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha; Zoledronic Acid

2004
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:7

    Topics: Animals; Arthritis, Experimental; Arthrography; Biomarkers; Bone Resorption; Diphosphonates; Female; Hindlimb; Imidazoles; Joints; Osteoclasts; Rats; Rats, Inbred Strains; Severity of Illness Index; Synovial Membrane; Synovitis; Tomography, X-Ray Computed; Zoledronic Acid

2004
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Journal of the National Cancer Institute, 2004, Oct-06, Volume: 96, Issue:19

    Topics: Bone Neoplasms; Bone Resorption; Controlled Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid

2004
Short-term safety assessment in the use of intravenous zoledronic acid in children.
    The Journal of pediatrics, 2004, Volume: 145, Issue:5

    Topics: Adolescent; Bone Resorption; Calcium; Child; Child, Preschool; Creatinine; Diphosphonates; Female; Fever; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Nausea; Pain; Phosphorus; Retrospective Studies; Time Factors; Urea; Vomiting; Zoledronic Acid

2004
Novel biomaterials for bisphosphonate delivery.
    Biomaterials, 2005, Volume: 26, Issue:14

    Topics: Animals; Biocompatible Materials; Bone Resorption; Calcium Phosphates; Cells, Cultured; Diphosphonates; Drug Carriers; Drug Implants; Imidazoles; Materials Testing; Osteoblasts; Rabbits; Surface Properties; Zoledronic Acid

2005
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Tennessee medicine : journal of the Tennessee Medical Association, 2005, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid

2005
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
    Biological trace element research, 2005, Volume: 104, Issue:2

    Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diphosphonates; Imidazoles; Isoenzymes; Magnesium; Osteoblasts; Osteosarcoma; Pamidronate; Rats; Tumor Cells, Cultured; Zinc; Zoledronic Acid

2005
Ask us: Some drugs affect tooth movement.
    American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics, 2005, Volume: 127, Issue:6

    Topics: Antineoplastic Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoclasts; Tooth Movement Techniques; Zoledronic Acid

2005
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteogenesis; Predictive Value of Tests; Prognosis; Zoledronic Acid

2005
[A comparison of the antiresorptive effects of bisphosphonates and statins on polyethylene particle-induced osteolysis].
    Biomedizinische Technik. Biomedical engineering, 2005, Volume: 50, Issue:6

    Topics: Animals; Bone Resorption; Diphosphonates; Female; Foreign-Body Reaction; Imidazoles; Male; Mice; Mice, Inbred C57BL; Osteolysis; Particle Size; Polyethylenes; Simvastatin; Skull; Treatment Outcome; Zoledronic Acid

2005
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2005, Volume: 23, Issue:4

    Topics: Animals; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Femur Head; Imidazoles; Legg-Calve-Perthes Disease; Rats; Rats, Inbred SHR; Zoledronic Acid

2005
Treatment of Paget's disease--taming the wild osteoclast.
    The New England journal of medicine, 2005, Sep-01, Volume: 353, Issue:9

    Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Resorption; Diphosphonates; Glycoproteins; Humans; Imidazoles; Osteitis Deformans; Osteoclasts; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid

2005
Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:10

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cartilage; Child; Child, Preschool; Diaphyses; Diphosphonates; Humans; Imidazoles; Osteogenesis Imperfecta; Osteoporosis; Rabbits; Tibia; Time Factors; Zoledronic Acid

2005
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2005, Volume: 33, Issue:6

    Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid

2005
[Osteoporosis and anti-androgenic therapy in case of prostate cancer].
    Revue medicale suisse, 2005, Oct-05, Volume: 1, Issue:35

    Topics: Androgen Antagonists; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Risk Factors; Survival; Zoledronic Acid

2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    BJU international, 2006, Volume: 97, Issue:3

    Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Urogenital Neoplasms; Zoledronic Acid

2006
Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling.
    Acta orthopaedica, 2006, Volume: 77, Issue:1

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Bone Transplantation; Diphosphonates; Female; Graft Rejection; Imidazoles; Male; Rats; Rats, Sprague-Dawley; Zoledronic Acid

2006
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
    Oncology reports, 2006, Volume: 15, Issue:5

    Topics: Adult; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid

2006
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    BJU international, 2006, Volume: 97, Issue:6

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Male; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid

2006
Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators.
    Microscopy research and technique, 2006, Volume: 69, Issue:8

    Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Image Processing, Computer-Assisted; Imidazoles; Membrane Glycoproteins; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Osteoclasts; Rabbits; RANK Ligand; Time Factors; Zoledronic Acid

2006
Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.
    BMC musculoskeletal disorders, 2006, Aug-04, Volume: 7

    Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Regeneration; Bone Remodeling; Bone Resorption; Bone Transplantation; Diffusion Chambers, Culture; Diphosphonates; Female; Graft Survival; Imidazoles; In Vitro Techniques; Male; Osteoclasts; Rats; Rats, Sprague-Dawley; Tibia; Zoledronic Acid

2006
Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.
    Internal medicine journal, 2006, Volume: 36, Issue:9

    Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Transplantation, Homologous; Zoledronic Acid

2006
Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Aftercare; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Early Diagnosis; Humans; Imidazoles; Nurse's Role; Nursing Assessment; Oncology Nursing; Pamidronate; Patient Care Planning; Patient Education as Topic; Quality of Life; Risk Assessment; Vitamin D; Zoledronic Acid

2006
The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro.
    Journal of biomedical materials research. Part A, 2007, Mar-15, Volume: 80, Issue:4

    Topics: Antigens, Differentiation; Bone Density Conservation Agents; Bone Resorption; Bone Substitutes; Cell Differentiation; Cells, Cultured; Coated Materials, Biocompatible; Diphosphonates; Humans; Imidazoles; Materials Testing; Osteoblasts; Osteoclasts; Polyesters; Zoledronic Acid

2007
Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2007, Volume: 25, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Infectious; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Interleukin-6; Mice; Osteoclasts; Osteoporosis; Staphylococcal Infections; Staphylococcus aureus; Zoledronic Acid

2007
Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007, Volume: 18, Issue:11

    Topics: Animals; Biomarkers; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Bone Transplantation; Cyclosporine; Diphosphonates; Drug Interactions; Fractures, Bone; Graft Survival; Imidazoles; Immunosuppressive Agents; Male; Osteogenesis; Osteoporosis; Rats; Rats, Inbred Lew; Tibia; Zoledronic Acid

2007
Bone turnover 18 months after a single intravenous dose of zoledronic acid.
    International journal of clinical practice, 2007, Volume: 61, Issue:6

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid

2007
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
    Journal of immunology (Baltimore, Md. : 1950), 2007, Jul-01, Volume: 179, Issue:1

    Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Immunologic; Female; Hydroxycholecalciferols; Hypercalcemia; Imidazoles; Immunity, Innate; Immunoglobulin G; Influenza A Virus, H3N2 Subtype; Longitudinal Studies; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Fusion Proteins; Zoledronic Acid

2007
Re: 'A single zoleledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density' by Saag et al.
    Bone, 2007, Volume: 41, Issue:4

    Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density; Bone Resorption; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Time Factors; Zoledronic Acid

2007
By the way, doctor. Should I take an intravenous drug for osteoporosis?
    Harvard women's health watch, 2007, Volume: 14, Issue:11

    Topics: Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Zoledronic Acid

2007
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Aug-28, Volume: 104, Issue:35

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Division; Diphosphonates; Imidazoles; Kinetics; Macrophages; Mice; Mice, Knockout; Neoplasm Metastasis; Osteoclasts; Receptors, CXCR4; Zoledronic Acid

2007
Zoledronic acid-induced IPP/ApppI production in vivo.
    Life sciences, 2007, Sep-08, Volume: 81, Issue:13

    Topics: Adenosine Triphosphate; Animals; Bone Density Conservation Agents; Bone Marrow Cells; Bone Resorption; Cells, Cultured; Diphosphonates; Geranyltranstransferase; Hemiterpenes; Imidazoles; Macrophages, Peritoneal; Mevalonic Acid; Mice; Organophosphorus Compounds; Time Factors; Zoledronic Acid

2007
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Clinical genitourinary cancer, 2007, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid

2007
Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse.
    Journal of applied physiology (Bethesda, Md. : 1985), 2008, Volume: 104, Issue:3

    Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Femur; Hindlimb Suspension; Imidazoles; Mice; Mice, Inbred C57BL; Osteoblasts; Osteogenesis; Osteoporosis; Osteoprotegerin; Space Flight; Tomography, X-Ray Computed; Weightlessness Countermeasures; Zoledronic Acid

2008
Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.
    Calcified tissue international, 2008, Volume: 82, Issue:3

    Topics: Animals; Bone Demineralization, Pathologic; Bone Density Conservation Agents; Bone Resorption; Compressive Strength; Diphosphonates; Disease Models, Animal; Elasticity; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Stress, Mechanical; Tibia; Tomography, X-Ray Computed; Zoledronic Acid

2008
Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Bone, 2008, Volume: 42, Issue:5

    Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Remodeling; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Endometrium; Estradiol; Female; Femur; Genistein; Genotype; Imidazoles; Isoenzymes; Liver; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Osteoprotegerin; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Tibia; Uterus; Zoledronic Acid

2008
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
    Oral oncology, 2008, Volume: 44, Issue:11

    Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Case-Control Studies; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid

2008
Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro.
    Journal of biomedical materials research. Part A, 2009, Volume: 89, Issue:1

    Topics: Animals; Apatites; Biocompatible Materials; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphates; Cells, Cultured; Diphosphonates; Drug Carriers; Drug Delivery Systems; Imidazoles; Materials Testing; Osteoblasts; Osteoclasts; Rabbits; Zoledronic Acid

2009
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Cancer, 2008, Jul-01, Volume: 113, Issue:1

    Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Peptides; Retrospective Studies; Survival Analysis; Treatment Outcome; Zoledronic Acid

2008
Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:1

    Topics: Acid Phosphatase; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Imidazoles; Isoenzymes; Mandible; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoprotegerin; Random Allocation; Tartrate-Resistant Acid Phosphatase; Tibia; Zoledronic Acid

2009
Effects of two novel bisphosphonates on bone cells in vitro.
    Bone and mineral, 1994, Volume: 26, Issue:2

    Topics: Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cells, Cultured; Culture Media, Conditioned; Diphosphonates; DNA; Dose-Response Relationship, Drug; Edetic Acid; Female; Humans; Imidazoles; Osteoblasts; Osteoclasts; Pamidronate; Rats; Tumor Cells, Cultured; Zoledronic Acid

1994
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:5

    Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Drug Evaluation, Preclinical; Hypercalcemia; Imidazoles; Interleukin-1; Male; Mice; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Parathyroidectomy; Peptide Fragments; Proteins; Rats; Thyroidectomy; Zoledronic Acid

1994
Zoledronate: the preclinical pharmacology.
    British journal of clinical practice. Supplement, 1996, Volume: 87

    Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Animal; Female; Hypercalcemia; Imidazoles; Ovariectomy; Pamidronate; Parathyroidectomy; Rats; Thyroidectomy; Zoledronic Acid

1996
Zoledronate in the treatment of osteolytic bone metastases.
    British journal of clinical practice. Supplement, 1996, Volume: 87

    Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Zoledronic Acid

1996
Research on bone metastases quickens its pace.
    Journal of the National Cancer Institute, 1997, Jun-18, Volume: 89, Issue:12

    Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid

1997
Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:11

    Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Female; Imidazoles; Macaca mulatta; Ovariectomy; Regression Analysis; Zoledronic Acid

1998
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1999, Volume: 14, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; Diphosphonates; Humans; Imidazoles; Interleukin-1; Interleukin-6; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid

1999
Zolendronate (zometa).
    The Medical letter on drugs and therapeutics, 2001, Dec-10, Volume: 43, Issue:1120

    Topics: Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Half-Life; Humans; Imidazoles; Zoledronic Acid

2001